Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

ULTRACET® Effective And Well Tolerated For Post-Surgical Pain

A new study published in the latest edition of a leading medical journal has shown that treatment with ULTRACET® (37.5 mg tramadol hydrochloride/325 mg acetaminophen tablets) demonstrates similar efficacy and better tolerability than TYLENOL® with Codeine No. 3 when each is compared to placebo.

5 Apr 2004

FDA has approved Zyprexa, injectable anti-psychotic drug

Physicians have a new fast-acting option for controlling the potentially crippling effects of acute agitation in patients suffering with schizophrenia and bipolar mania. The U.S. Food and Drug Administration (FDA) has approved Zyprexa® IntraMuscular (olanzapine for injection), an injectable form of Lilly's top-selling medication.

30 Mar 2004

A simple dietary supplement may also help to prevent strokes

A simple dietary supplement may not only give relief to some of the more than 400,000 New Zealanders that suffer from the pain of migraine headaches, but may also help to prevent strokes.

28 Mar 2004

Anti-ageing formula recalled due to excessive vitamin D3

Aloe Commodities International, Inc., Carrollton, Texas, is recalling 1600 bottles of Solutions IE Ageless Formula II, Lot numbers P2207 and P2221 because they contain a significantly higher-than-labeled level of vitamin D3. (Approximately 188,640 International Units (IU) are present in each serving size of 6 capsules instead of the intended level of 400 IU). The product is distributed by Solutions International, Inc., Orem, UT.

27 Mar 2004

Raptiva, 20 percent improvement in an individual's signs and symptoms of arthritis.

Genentech, Inc. and XOMA Ltd. today announced preliminary results of a randomized, placebo-controlled Phase II study with RAPTIVA™ (efalizumab) in 107 patients with psoriatic arthritis. The study did not reach statistical significance at 12 weeks (84 days) for the primary endpoint, ACR 20 response. An ACR 20 response indicates at least a 20 percent improvement in an individual's signs and symptoms of arthritis.

22 Mar 2004

New drug to treat urinary tract infections, a step closer

Depomed, Inc. today announced top line results from the Phase III clinical trial of its Ciprofloxacin GR, an extended release formulation of ciprofloxacin HCl, which is used to treat urinary tract infections. The data confirmed Phase II results, demonstrating that Depomed's once-daily Ciprofloxacin GR eliminated the organisms responsible for urinary tract infections as effectively as twice-daily CIPRO(R), but with fewer gastrointestinal side effects, specifically fewer incidences of nausea and diarrhea.

22 Mar 2004